Candel Halts Development of CAN-2409 for Prostate Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy CADL?
Source: SeekingAlpha
Development Pause: Candel Therapeutics is pausing the development of CAN-2409 for borderline resectable pancreatic adenocarcinoma to focus on localized, intermediate/high risk pancreatic cancer and non-small cell lung cancer (NSCLC).
Clinical Trials Update: The company is preparing for a Biologics License Application (BLA) submission for CAN-2409 in localized pancreatic cancer and plans to initiate a phase 3 study in NSCLC by Q2 2026.
Financial Performance: Candel's Q3 financial results fell short of expectations, indicating challenges in their financial performance.
Market Reactions: The stock prices of Candel and other biopharma companies like Erasca and Xencor have declined following a downgrade by BofA due to a perceived lack of near-term catalysts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.370
Low
7.00
Averages
18.33
High
25.00
Current: 6.370
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Candel Therapeutics Stock Seen as Deeply Undervalued Ahead of Key Trial Data
- Valuation Insights: Cantor Fitzgerald initiated coverage of Candel Therapeutics with an 'Overweight' rating, highlighting a discounted cash flow estimate of around $30 per share, indicating a potential 370% upside that reflects strong market confidence in the stock's future performance.
- Clinical Trial Progress: Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer, with 50% of patients still alive at two years after one year of follow-up, demonstrating the therapy's potential in activating the immune system and improving survival rates.
- Strong Market Reaction: Candel's stock drew significant retail interest on Monday, with message volume on Stocktwits surging by approximately 70%, reflecting investor optimism ahead of key trial data releases.
- Future Outlook: Investors are eagerly awaiting extended phase 3 results for CAN-2409 in prostate cancer at the 2026 American Urological Association meeting, as well as updates on other programs like CAN-3110, which will further influence the company's market performance.
See More
Candel Therapeutics Shares Surge 24% on Positive Trial News
- Stock Surge: Candel Therapeutics shares jumped 24% on Friday as investors anticipate upcoming clinical data, potentially marking the best trading day since December 2024, reflecting strong market confidence in the company's future prospects.
- Positive Media Coverage: CEO Paul Peter Tak highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, on social media, emphasizing the potential of the company's viral immunotherapy CAN-3110 to reshape the tumor microenvironment and activate durable immune responses, which holds significant scientific importance.
- Clinical Trial Developments: Candel is planning a late-stage trial in non-small cell lung cancer and will present new data from the randomized late-stage trial of CAN-2409 in localized prostate cancer at the American Urological Association (AUA) meeting in May 2026, further fueling investor anticipation.
- Retail Trader Sentiment Shift: On Stocktwits, retail sentiment around CADL stock shifted from 'neutral' to 'extremely bullish' in the past 24 hours, with message volume rising from 'normal' to 'extremely high', indicating optimism for potential buyouts or partnerships for the company.
See More
Candel Therapeutics Reports Positive Mid-Stage Trial Results for CAN-2409
- Survival Rate Improvement: Candel Therapeutics reported that in its ongoing Phase 2a trial, 50% of patients receiving CAN-2409 combination therapy were alive at 24 months, a significant increase from the previous 39%, indicating the lasting antitumor effects of the therapy.
- Trial Design: The open-label trial was designed to evaluate the efficacy of aglatimagene combined with valacyclovir and PD-((L))1 checkpoint inhibitors in patients with advanced non-small cell lung cancer who did not adequately respond to PD-((L))1 therapy, showcasing promising clinical outcomes.
- Future Plans: Candel plans to expand the program into a pivotal Phase 3 trial focusing on non-squamous histology NSCLC, with trial initiation expected in Q2 2026, aiming to further validate the efficacy of its therapy.
- Market Reaction: Following the announcement of positive trial results, Candel's stock traded higher on Tuesday, reflecting investor optimism regarding the potential of its immunotherapy, which may attract further investment and attention.
See More
Candel Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Candel Therapeutics reported a GAAP EPS of -$0.54 for Q4 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $119.7 million, up from $102.7 million as of December 31, 2024, reflecting improvements in cash management.
- Funding Outlook: Based on current operating plans, the company expects its existing cash and cash equivalents, along with proceeds from the follow-on equity offering in February 2026, to fund operations into Q1 2028, demonstrating confidence in future liquidity.
- Stock Offering Plan: Candel Therapeutics is launching a $100 million public stock offering; while this may lead to a decline in share price, it provides essential funding to meet future operational needs.
See More
Candel Therapeutics Announces Public Offering Pricing
- Public Offering Pricing: Candel Therapeutics has priced an underwritten public offering of approximately 18.35 million shares at $5.45 per share, aiming to raise about $100 million to support critical launch readiness and ongoing development costs for its cancer therapies.
- Clear Use of Proceeds: The funds will be allocated towards the launch readiness of its lead product candidate, aglatimagene besadenovec (CAN-2409), and ongoing development for its phase 3 trial in non-small cell lung cancer (NSCLC), highlighting the company's commitment to advancing its viral immunotherapy pipeline.
- Weak Stock Performance: Candel's shares fell 11.43% to $5.27 during premarket trading, trading 10.4% below its 20-day and 50-day simple moving averages, indicating bearish market sentiment surrounding the stock.
- Optimistic Analyst Ratings: Despite the stock's decline, it maintains a Buy rating with an average price target of $15.77, reflecting analysts' confidence in the company's future growth, particularly given the positive clinical trial results for its product candidate.
See More
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
Candel Therapeutics Stock Seen as Deeply Undervalued Ahead of Key Trial Data
- Valuation Insights: Cantor Fitzgerald initiated coverage of Candel Therapeutics with an 'Overweight' rating, highlighting a discounted cash flow estimate of around $30 per share, indicating a potential 370% upside that reflects strong market confidence in the stock's future performance.
- Clinical Trial Progress: Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer, with 50% of patients still alive at two years after one year of follow-up, demonstrating the therapy's potential in activating the immune system and improving survival rates.
- Strong Market Reaction: Candel's stock drew significant retail interest on Monday, with message volume on Stocktwits surging by approximately 70%, reflecting investor optimism ahead of key trial data releases.
- Future Outlook: Investors are eagerly awaiting extended phase 3 results for CAN-2409 in prostate cancer at the 2026 American Urological Association meeting, as well as updates on other programs like CAN-3110, which will further influence the company's market performance.
See More
Candel Therapeutics Shares Surge 24% on Positive Trial News
- Stock Surge: Candel Therapeutics shares jumped 24% on Friday as investors anticipate upcoming clinical data, potentially marking the best trading day since December 2024, reflecting strong market confidence in the company's future prospects.
- Positive Media Coverage: CEO Paul Peter Tak highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, on social media, emphasizing the potential of the company's viral immunotherapy CAN-3110 to reshape the tumor microenvironment and activate durable immune responses, which holds significant scientific importance.
- Clinical Trial Developments: Candel is planning a late-stage trial in non-small cell lung cancer and will present new data from the randomized late-stage trial of CAN-2409 in localized prostate cancer at the American Urological Association (AUA) meeting in May 2026, further fueling investor anticipation.
- Retail Trader Sentiment Shift: On Stocktwits, retail sentiment around CADL stock shifted from 'neutral' to 'extremely bullish' in the past 24 hours, with message volume rising from 'normal' to 'extremely high', indicating optimism for potential buyouts or partnerships for the company.
See More
Candel Therapeutics Reports Positive Mid-Stage Trial Results for CAN-2409
- Survival Rate Improvement: Candel Therapeutics reported that in its ongoing Phase 2a trial, 50% of patients receiving CAN-2409 combination therapy were alive at 24 months, a significant increase from the previous 39%, indicating the lasting antitumor effects of the therapy.
- Trial Design: The open-label trial was designed to evaluate the efficacy of aglatimagene combined with valacyclovir and PD-((L))1 checkpoint inhibitors in patients with advanced non-small cell lung cancer who did not adequately respond to PD-((L))1 therapy, showcasing promising clinical outcomes.
- Future Plans: Candel plans to expand the program into a pivotal Phase 3 trial focusing on non-squamous histology NSCLC, with trial initiation expected in Q2 2026, aiming to further validate the efficacy of its therapy.
- Market Reaction: Following the announcement of positive trial results, Candel's stock traded higher on Tuesday, reflecting investor optimism regarding the potential of its immunotherapy, which may attract further investment and attention.
See More
Candel Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Candel Therapeutics reported a GAAP EPS of -$0.54 for Q4 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $119.7 million, up from $102.7 million as of December 31, 2024, reflecting improvements in cash management.
- Funding Outlook: Based on current operating plans, the company expects its existing cash and cash equivalents, along with proceeds from the follow-on equity offering in February 2026, to fund operations into Q1 2028, demonstrating confidence in future liquidity.
- Stock Offering Plan: Candel Therapeutics is launching a $100 million public stock offering; while this may lead to a decline in share price, it provides essential funding to meet future operational needs.
See More
Candel Therapeutics Announces Public Offering Pricing
- Public Offering Pricing: Candel Therapeutics has priced an underwritten public offering of approximately 18.35 million shares at $5.45 per share, aiming to raise about $100 million to support critical launch readiness and ongoing development costs for its cancer therapies.
- Clear Use of Proceeds: The funds will be allocated towards the launch readiness of its lead product candidate, aglatimagene besadenovec (CAN-2409), and ongoing development for its phase 3 trial in non-small cell lung cancer (NSCLC), highlighting the company's commitment to advancing its viral immunotherapy pipeline.
- Weak Stock Performance: Candel's shares fell 11.43% to $5.27 during premarket trading, trading 10.4% below its 20-day and 50-day simple moving averages, indicating bearish market sentiment surrounding the stock.
- Optimistic Analyst Ratings: Despite the stock's decline, it maintains a Buy rating with an average price target of $15.77, reflecting analysts' confidence in the company's future growth, particularly given the positive clinical trial results for its product candidate.
See More
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
